Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 3Terminated 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Locally Advanced Esophageal or GE Junction Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24venetoclax 23Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23Azacitidine 23Ipilimumab 22Fluorouracil 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × gossypol acetic acid × Clear all
NCT01003769 2020-06-16

Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

Mayo Clinic

Phase 1/2 Terminated
5 enrolled 7 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00561197 2013-01-04

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

Ascenta Therapeutics

Phase 1/2 Terminated
13 enrolled
Gastrointestinal

Locally Advanced Esophageal or GE Junction Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡